A clinical case of atopic dermatitis with a rapid positive effect from the use of a genetically engineered biological drug in a teenager

• Main Authors: E. V. Churyukina (Author), E. A. Portnyaga (Author)
• Format: Book
• Published: Association of Paediatric Allergists and Immunologists of Russia (APAIR), 2024-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Introduction. The instructions for the drug dupilumab indicate that the administration of a single loading dose on the first day leads to the rapid achievement of clinically effective concentrations within 2 weeks, which we saw in the example of our patient and her real clinical response to the first injection.   Presentation of a clinical case. Under our medical supervision was a 17-year-old patient with severe atopic dermatitis, resistant to traditional therapy. Heredity for allergic pathology is burdened: the girl's mother suffers from pollen allergy. Initially before the start of therapy: SCORAD - 88 points, EASI - 48.8 points, IGA - 4, blood eosinophils - 11 % (1188 cells/ml), total IgE - 1102.0 IU/ml; the content of nitric oxide in exhaled air (FeNO) is 30 ppb. On April 28, 2021, the patient was administered dupilumab at a dose of 600 mg. Assessment of atopic dermatitis control in points upon admission to the hospital 2 weeks after the first administration of dupilumab: on the SCORAD scale - 44.5 points; EASI - 13.8 points; IGA - 2 points, eosinophils - 9 % (1070 cells/ml); total IgE - 840 IU/ml; FeNO - 5 ppb.   Conclusion. This clinical observation clearly illustrates the fact that patients with severe atopic dermatitis who don't respond to first-line therapy can achieve positive clinical results after the first use of a recombinant human monoclonal antibody (IgG4).

Item Description

2500-1175
2712-7958
10.53529/2500-1175-2024-1-20-26